Technical Analysis for AMGN - Amgen Inc.

Grade Last Price % Change Price Change
grade F 188.34 0.89% 1.66
AMGN closed up 0.89 percent on Friday, February 15, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical AMGN trend table...

Date Alert Name Type % Chg
Feb 15 Cup with Handle Other 0.00%
Feb 14 Cup with Handle Other 0.89%
Feb 14 Narrow Range Bar Range Contraction 0.89%
Feb 14 Gapped Down Weakness 0.89%
Feb 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.34%
Feb 13 Cup with Handle Other -0.34%
Feb 13 Narrow Range Bar Range Contraction -0.34%
Feb 13 Multiple of Ten Bearish Other -0.34%
Feb 12 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.05%
Feb 12 Cup with Handle Other -0.05%

Older signals for AMGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB, as well as a strategic alliance with Astellas Pharma Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Medicine Biotechnology Drugs Pharmaceutical Products Healthcare Providers Inflammation Dialysis Neuroscience Inflammatory Diseases Wholesale Distributors Cancer Care Amgen Recombinant Proteins Castration Resistant Prostate Cancer Growth Factors Human Therapeutic Products Thrombopoietin Receptor Agonists
Is AMGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 210.19
52 Week Low 163.31
Average Volume 3,278,678
200-Day Moving Average 192.1869
50-Day Moving Average 192.6772
20-Day Moving Average 191.198
10-Day Moving Average 187.37
Average True Range 4.0849
ADX 25.83
+DI 20.0603
-DI 30.4137
Chandelier Exit (Long, 3 ATRs ) 192.0753
Chandelier Exit (Short, 3 ATRs ) 191.9047
Upper Bollinger Band 203.7861
Lower Bollinger Band 178.6099
Percent B (%b) 0.39
BandWidth 13.167606
MACD Line -2.1932
MACD Signal Line -2.0491
MACD Histogram -0.144
Fundamentals Value
Market Cap 137.43 Billion
Num Shares 730 Million
EPS 10.98
Price-to-Earnings (P/E) Ratio 17.15
Price-to-Sales 5.59
Price-to-Book 4.07
PEG Ratio 3.29
Dividend 4.60
Dividend Yield 2.44%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 193.01
Resistance 3 (R3) 192.74 190.92 192.23
Resistance 2 (R2) 190.92 189.73 191.05 191.97
Resistance 1 (R1) 189.63 189.00 190.28 189.90 191.71
Pivot Point 187.81 187.81 188.13 187.94 187.81
Support 1 (S1) 186.52 186.62 187.17 186.79 184.97
Support 2 (S2) 184.70 185.89 184.83 184.71
Support 3 (S3) 183.41 184.70 184.45
Support 4 (S4) 183.68